Skip to main content
Top
Published in: BMC Surgery 1/2014

Open Access 01-12-2014 | Research article

Long term follow up and retrospective study on 533 gastric cancer cases

Authors: Wei-Juan Zeng, Wen-Qin Hu, Lin-Wei Wang, Shu-Guang Yan, Jian-Ding Li, Hao-Liang Zhao, Chun-Wei Peng, Gui-Fang Yang, Yan Li

Published in: BMC Surgery | Issue 1/2014

Login to get access

Abstract

Background

Gastric cancer (GC) is the third leading cause of cancer death in China and the outcome of GC patients is poor. The aim of the research is to study the prognostic factors of gastric cancer patients who had curative intent or palliative resection, completed clinical database and follow-up.

Methods

This retrospective study analyzed 533 GC patients from three tertiary referral teaching hospitals from January 2004 to December 2010 who had curative intent or palliative resection, complete clinical database and follow-up information. The GC-specific overall survival (OS) status was determined by the Kaplan-Meier method, and univariate analysis was conducted to identify possible factors for survival. Multivariate analysis using the Cox proportional hazard model and a forward regression procedure was conducted to define independent prognostic factors.

Results

By the last follow-up, the median follow-up time of 533 GC patients was 38.6 mo (range 6.9-100.9 mo), and the median GC-specific OS was 25.3 mo (95% CI: 23.1-27.4 mo). The estimated 1-, 2-, 3- and 5-year GC-specific OS rates were 78.4%, 61.4%, 53.3% and 48.4%, respectively. Univariate analysis identified the following prognostic factors: hospital, age, gender, cancer site, surgery type, resection type, other organ resection, HIPEC, LN status, tumor invasion, distant metastases, TNM stage, postoperative SAE, systemic chemotherapy and IP chemotherapy. In multivariate analysis, seven factors were identified as independent prognostic factors for long term survival, including resection type, HIPEC, LN status, tumor invasion, distant metastases, postoperative SAE and systemic chemotherapy.

Conclusions

Resection type, HIPEC, postoperative SAE and systemic chemotherapy are four independent prognostic factors that could be intervened for GC patients for improving survival.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in, GLOBOCAN 2008. Int J Cancer. 2008, 2010 (127): 2893-2917. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in, GLOBOCAN 2008. Int J Cancer. 2008, 2010 (127): 2893-2917.
2.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.CrossRefPubMed
5.
go back to reference Wang W, Sun XW, Li CF, Lv L, Li YF, Chen YB, Xu DZ, Kesari R, Huang CY, Li W, Zhan YQ, Zhou ZW: Comparison of the 6th and 7th editions of the UICC TNM staging system for gastric cancer: results of a Chinese single-institution study of 1,503 patients. Ann Surg Oncol. 2011, 18: 1060-1067. 10.1245/s10434-010-1424-2.CrossRefPubMed Wang W, Sun XW, Li CF, Lv L, Li YF, Chen YB, Xu DZ, Kesari R, Huang CY, Li W, Zhan YQ, Zhou ZW: Comparison of the 6th and 7th editions of the UICC TNM staging system for gastric cancer: results of a Chinese single-institution study of 1,503 patients. Ann Surg Oncol. 2011, 18: 1060-1067. 10.1245/s10434-010-1424-2.CrossRefPubMed
6.
go back to reference Chen C, Chen LQ, Chen LD, Yang GL, Li Y: Evaluation of tumor markers biochip C12 system in the diagnosis of gastric cancer and the strategies for improvement: analysis of 100 cases. Hepatogastroenterology. 2008, 55: 991-997.PubMed Chen C, Chen LQ, Chen LD, Yang GL, Li Y: Evaluation of tumor markers biochip C12 system in the diagnosis of gastric cancer and the strategies for improvement: analysis of 100 cases. Hepatogastroenterology. 2008, 55: 991-997.PubMed
7.
go back to reference Wu HL, Tian Q, Peng CW, Liu SP, Li Y: Multivariate survival and outcome analysis of 154 patients with gastric cancer at a single Chinese institution. Asian Pac J Cancer Prev. 2011, 12: 3341-3345.PubMed Wu HL, Tian Q, Peng CW, Liu SP, Li Y: Multivariate survival and outcome analysis of 154 patients with gastric cancer at a single Chinese institution. Asian Pac J Cancer Prev. 2011, 12: 3341-3345.PubMed
8.
go back to reference Zhang XF, Huang CM, Lu HS, Wu XY, Wang C, Guang GX, Zhang JZ, Zheng CH: Surgical treatment and prognosis of gastric cancer in 2,613 patients. World J Gastroenterol. 2004, 10: 3405-3408.CrossRefPubMedPubMedCentral Zhang XF, Huang CM, Lu HS, Wu XY, Wang C, Guang GX, Zhang JZ, Zheng CH: Surgical treatment and prognosis of gastric cancer in 2,613 patients. World J Gastroenterol. 2004, 10: 3405-3408.CrossRefPubMedPubMedCentral
9.
go back to reference Li BS, Zhao YL, Guo G, Li W, Zhu ED, Luo X, Mao XH, Zou QM, Yu PW, Zuo QF, Li N, Tang B, Liu KY, Xiao B: Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One. 2012, 7: e41629-10.1371/journal.pone.0041629.CrossRefPubMedPubMedCentral Li BS, Zhao YL, Guo G, Li W, Zhu ED, Luo X, Mao XH, Zou QM, Yu PW, Zuo QF, Li N, Tang B, Liu KY, Xiao B: Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One. 2012, 7: e41629-10.1371/journal.pone.0041629.CrossRefPubMedPubMedCentral
10.
go back to reference Yokota T, Ishiyama S, Saito T, Teshima S, Shimotsuma M, Yamauchi H: Treatment strategy of limited surgery in the treatment guidelines for gastric cancer in Japan. Lancet Oncol. 2003, 4: 423-428. 10.1016/S1470-2045(03)01140-9.CrossRefPubMed Yokota T, Ishiyama S, Saito T, Teshima S, Shimotsuma M, Yamauchi H: Treatment strategy of limited surgery in the treatment guidelines for gastric cancer in Japan. Lancet Oncol. 2003, 4: 423-428. 10.1016/S1470-2045(03)01140-9.CrossRefPubMed
11.
go back to reference Diaz DLA, Yarnoz C, Aguilar R, Artieda C, Ortiz H: Rationale for gastrectomy with D2 lymphadenectomy in the treatment of gastric cancer. Gastric Cancer. 2008, 11: 96-102. 10.1007/s10120-008-0460-0.CrossRef Diaz DLA, Yarnoz C, Aguilar R, Artieda C, Ortiz H: Rationale for gastrectomy with D2 lymphadenectomy in the treatment of gastric cancer. Gastric Cancer. 2008, 11: 96-102. 10.1007/s10120-008-0460-0.CrossRef
12.
go back to reference D'Annibale A, Pende V, Pernazza G, Monsellato I, Mazzocchi P, Lucandri G, Morpurgo E, Contardo T, Sovernigo G: Full robotic gastrectomy with extended (D2) lymphadenectomy for gastric cancer: surgical technique and preliminary results. J Surg Res. 2011, 166: e113-e120. 10.1016/j.jss.2010.11.881.CrossRefPubMed D'Annibale A, Pende V, Pernazza G, Monsellato I, Mazzocchi P, Lucandri G, Morpurgo E, Contardo T, Sovernigo G: Full robotic gastrectomy with extended (D2) lymphadenectomy for gastric cancer: surgical technique and preliminary results. J Surg Res. 2011, 166: e113-e120. 10.1016/j.jss.2010.11.881.CrossRefPubMed
13.
go back to reference Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ: Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010, 11: 439-449. 10.1016/S1470-2045(10)70070-X.CrossRefPubMed Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ: Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010, 11: 439-449. 10.1016/S1470-2045(10)70070-X.CrossRefPubMed
14.
go back to reference Washington K: 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 2010, 17: 3077-3079. 10.1245/s10434-010-1362-z.CrossRefPubMed Washington K: 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol. 2010, 17: 3077-3079. 10.1245/s10434-010-1362-z.CrossRefPubMed
15.
go back to reference Ajani JA, Bentrem DJ, Besh S, D'Amico TA, Das P, Denlinger C, Fakih MG, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn WM, Lockhart AC, Meredith K, Mulcahy MF, Orringer MB, Posey JA, Sasson AR, Scott WJ, Strong VE, Varghese TJ, Warren G, Washington MK, Willett C, Wright CD, McMillian NR: Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013, 11: 531-546.PubMed Ajani JA, Bentrem DJ, Besh S, D'Amico TA, Das P, Denlinger C, Fakih MG, Fuchs CS, Gerdes H, Glasgow RE, Hayman JA, Hofstetter WL, Ilson DH, Keswani RN, Kleinberg LR, Korn WM, Lockhart AC, Meredith K, Mulcahy MF, Orringer MB, Posey JA, Sasson AR, Scott WJ, Strong VE, Varghese TJ, Warren G, Washington MK, Willett C, Wright CD, McMillian NR: Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2013, 11: 531-546.PubMed
16.
go back to reference Yonemura Y, Endou Y, Sasaki T, Hirano M, Mizumoto A, Matsuda T, Takao N, Ichinose M, Miura M, Li Y: Surgical treatment for peritoneal carcinomatosis from gastric cancer. Eur J Surg Oncol. 2010, 36: 1131-1138. 10.1016/j.ejso.2010.09.006.CrossRefPubMed Yonemura Y, Endou Y, Sasaki T, Hirano M, Mizumoto A, Matsuda T, Takao N, Ichinose M, Miura M, Li Y: Surgical treatment for peritoneal carcinomatosis from gastric cancer. Eur J Surg Oncol. 2010, 36: 1131-1138. 10.1016/j.ejso.2010.09.006.CrossRefPubMed
17.
go back to reference Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007, 357: 1810-1820. 10.1056/NEJMoa072252.CrossRefPubMed Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007, 357: 1810-1820. 10.1056/NEJMoa072252.CrossRefPubMed
18.
go back to reference Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001, 345: 725-730. 10.1056/NEJMoa010187.CrossRefPubMed Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001, 345: 725-730. 10.1056/NEJMoa010187.CrossRefPubMed
19.
go back to reference Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC TP: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006, 355: 11-20. 10.1056/NEJMoa055531.CrossRefPubMed Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC TP: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006, 355: 11-20. 10.1056/NEJMoa055531.CrossRefPubMed
20.
go back to reference Shiraishi N, Inomata M, Osawa N, Yasuda K, Adachi Y, Kitano S: Early and late recurrence after gastrectomy for gastric carcinoma: Univariate and multivariate analyses. Cancer. 2000, 89: 255-261. 10.1002/1097-0142(20000715)89:2<255::AID-CNCR8>3.0.CO;2-N.CrossRefPubMed Shiraishi N, Inomata M, Osawa N, Yasuda K, Adachi Y, Kitano S: Early and late recurrence after gastrectomy for gastric carcinoma: Univariate and multivariate analyses. Cancer. 2000, 89: 255-261. 10.1002/1097-0142(20000715)89:2<255::AID-CNCR8>3.0.CO;2-N.CrossRefPubMed
21.
go back to reference Kodera Y, Ito S, Yamamura Y, Mochizuki Y, Fujiwara M, Hibi K, Ito K, Akiyama S, Nakao A: Follow-up surveillance for recurrence after curative gastric cancer surgery lacks survival benefit. Ann Surg Oncol. 2003, 10: 898-902. 10.1245/ASO.2003.12.009.CrossRefPubMed Kodera Y, Ito S, Yamamura Y, Mochizuki Y, Fujiwara M, Hibi K, Ito K, Akiyama S, Nakao A: Follow-up surveillance for recurrence after curative gastric cancer surgery lacks survival benefit. Ann Surg Oncol. 2003, 10: 898-902. 10.1245/ASO.2003.12.009.CrossRefPubMed
22.
go back to reference Yoo CH, Noh SH, Shin DW, Choi SH, Min JS: Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000, 87: 236-242. 10.1046/j.1365-2168.2000.01360.x.CrossRefPubMed Yoo CH, Noh SH, Shin DW, Choi SH, Min JS: Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000, 87: 236-242. 10.1046/j.1365-2168.2000.01360.x.CrossRefPubMed
23.
go back to reference Yang XQ, Yan L, Chen C, Hou JX, Li Y: Application of C12 multi-tumor marker protein chip in the diagnosis of gastrointestinal cancer: results of 329 surgical patients and suggestions for improvement. Hepatogastroenterology. 2009, 56: 1388-1394.PubMed Yang XQ, Yan L, Chen C, Hou JX, Li Y: Application of C12 multi-tumor marker protein chip in the diagnosis of gastrointestinal cancer: results of 329 surgical patients and suggestions for improvement. Hepatogastroenterology. 2009, 56: 1388-1394.PubMed
24.
go back to reference Yang D, Hendifar A, Lenz C, Togawa K, Lenz F, Lurje G, Pohl A, Winder T, Ning Y, Groshen S, Lenz HJ: Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity. J Gastrointest Oncol. 2011, 2: 77-84.PubMedPubMedCentral Yang D, Hendifar A, Lenz C, Togawa K, Lenz F, Lurje G, Pohl A, Winder T, Ning Y, Groshen S, Lenz HJ: Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity. J Gastrointest Oncol. 2011, 2: 77-84.PubMedPubMedCentral
25.
go back to reference Nanthakumaran S, Fernandes E, Thompson AM, Rapson T, Gilbert FJ, Park KG: Morbidity and mortality rates following gastric cancer surgery and contiguous organ removal, a population based study. Eur J Surg Oncol. 2005, 31: 1141-1144. 10.1016/j.ejso.2005.03.013.CrossRefPubMed Nanthakumaran S, Fernandes E, Thompson AM, Rapson T, Gilbert FJ, Park KG: Morbidity and mortality rates following gastric cancer surgery and contiguous organ removal, a population based study. Eur J Surg Oncol. 2005, 31: 1141-1144. 10.1016/j.ejso.2005.03.013.CrossRefPubMed
26.
go back to reference Li C, Yan M, Chen J, Xiang M, Zhu ZG, Yin HR, Lin YZ: Surgical resection with hyperthermic intraperitoneal chemotherapy for gastric cancer patients with peritoneal dissemination. J Surg Oncol. 2010, 102: 361-365. 10.1002/jso.21628.CrossRefPubMed Li C, Yan M, Chen J, Xiang M, Zhu ZG, Yin HR, Lin YZ: Surgical resection with hyperthermic intraperitoneal chemotherapy for gastric cancer patients with peritoneal dissemination. J Surg Oncol. 2010, 102: 361-365. 10.1002/jso.21628.CrossRefPubMed
27.
go back to reference Landry CS, Brock G, Scoggins CR, McMasters KM, Martin RN: A proposed staging system for gastric carcinoid tumors based on an analysis of 1,543 patients. Ann Surg Oncol. 2009, 16: 51-60. 10.1245/s10434-008-0192-8.CrossRefPubMed Landry CS, Brock G, Scoggins CR, McMasters KM, Martin RN: A proposed staging system for gastric carcinoid tumors based on an analysis of 1,543 patients. Ann Surg Oncol. 2009, 16: 51-60. 10.1245/s10434-008-0192-8.CrossRefPubMed
28.
go back to reference Cheong JH, Shen JY, Song CS, Hyung WJ, Shen JG, Choi SH, Noh SH: Early postoperative intraperitoneal chemotherapy following cytoreductive surgery in patients with very advanced gastric cancer. Ann Surg Oncol. 2007, 14: 61-68.CrossRefPubMed Cheong JH, Shen JY, Song CS, Hyung WJ, Shen JG, Choi SH, Noh SH: Early postoperative intraperitoneal chemotherapy following cytoreductive surgery in patients with very advanced gastric cancer. Ann Surg Oncol. 2007, 14: 61-68.CrossRefPubMed
29.
go back to reference Heise K, Bertran E, Andia ME, Ferreccio C: Incidence and survival of stomach cancer in a high-risk population of Chile. World J Gastroenterol. 2009, 15: 1854-1862. 10.3748/wjg.15.1854.CrossRefPubMedPubMedCentral Heise K, Bertran E, Andia ME, Ferreccio C: Incidence and survival of stomach cancer in a high-risk population of Chile. World J Gastroenterol. 2009, 15: 1854-1862. 10.3748/wjg.15.1854.CrossRefPubMedPubMedCentral
30.
go back to reference Glehen O, Schreiber V, Cotte E, Sayag-Beaujard AC, Osinsky D, Freyer G, Francois Y, Vignal J, Gilly FN: Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg. 2004, 139: 20-26. 10.1001/archsurg.139.1.20.CrossRefPubMed Glehen O, Schreiber V, Cotte E, Sayag-Beaujard AC, Osinsky D, Freyer G, Francois Y, Vignal J, Gilly FN: Cytoreductive surgery and intraperitoneal chemohyperthermia for peritoneal carcinomatosis arising from gastric cancer. Arch Surg. 2004, 139: 20-26. 10.1001/archsurg.139.1.20.CrossRefPubMed
31.
go back to reference Yonemura Y, Kawamura T, Bandou E, Takahashi S, Sawa T, Matsuki N: Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg. 2005, 92: 370-375. 10.1002/bjs.4695.CrossRefPubMed Yonemura Y, Kawamura T, Bandou E, Takahashi S, Sawa T, Matsuki N: Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg. 2005, 92: 370-375. 10.1002/bjs.4695.CrossRefPubMed
32.
go back to reference Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y, Li Y: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011, 18: 1575-1581. 10.1245/s10434-011-1631-5.CrossRefPubMedPubMedCentral Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y, Li Y: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011, 18: 1575-1581. 10.1245/s10434-011-1631-5.CrossRefPubMedPubMedCentral
33.
go back to reference Yan TD, Black D, Sugarbaker PH, Zhu J, Yonemura Y, Petrou G, Morris DL: A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol. 2007, 14: 2702-2713. 10.1245/s10434-007-9487-4.CrossRefPubMed Yan TD, Black D, Sugarbaker PH, Zhu J, Yonemura Y, Petrou G, Morris DL: A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol. 2007, 14: 2702-2713. 10.1245/s10434-007-9487-4.CrossRefPubMed
34.
go back to reference Sierzega M, Kolodziejczyk P, Kulig J: Impact of anastomotic leakage on long-term survival after total gastrectomy for carcinoma of the stomach. Br J Surg. 2010, 97: 1035-1042. 10.1002/bjs.7038.CrossRefPubMed Sierzega M, Kolodziejczyk P, Kulig J: Impact of anastomotic leakage on long-term survival after total gastrectomy for carcinoma of the stomach. Br J Surg. 2010, 97: 1035-1042. 10.1002/bjs.7038.CrossRefPubMed
35.
go back to reference Yoo HM, Lee HH, Shim JH, Jeon HM, Park CH, Song KY: Negative impact of leakage on survival of patients undergoing curative resection for advanced gastric cancer. J Surg Oncol. 2011, 104: 734-740. 10.1002/jso.22045.CrossRefPubMed Yoo HM, Lee HH, Shim JH, Jeon HM, Park CH, Song KY: Negative impact of leakage on survival of patients undergoing curative resection for advanced gastric cancer. J Surg Oncol. 2011, 104: 734-740. 10.1002/jso.22045.CrossRefPubMed
36.
go back to reference Kubota T, Hiki N, Sano T, Nomura S, Nunobe S, Kumagai K, Aikou S, Watanabe R, Kosuga T, Yamaguchi T: Prognostic significance of complications after curative surgery for gastric cancer. Ann Surg Oncol. 2014, 21: 891-898. 10.1245/s10434-013-3384-9.CrossRefPubMed Kubota T, Hiki N, Sano T, Nomura S, Nunobe S, Kumagai K, Aikou S, Watanabe R, Kosuga T, Yamaguchi T: Prognostic significance of complications after curative surgery for gastric cancer. Ann Surg Oncol. 2014, 21: 891-898. 10.1245/s10434-013-3384-9.CrossRefPubMed
37.
go back to reference Tokunaga M, Tanizawa Y, Bando E, Kawamura T, Terashima M: Poor survival rate in patients with postoperative intra-abdominal infectious complications following curative gastrectomy for gastric cancer. Ann Surg Oncol. 2013, 20: 1575-1583. 10.1245/s10434-012-2720-9.CrossRefPubMed Tokunaga M, Tanizawa Y, Bando E, Kawamura T, Terashima M: Poor survival rate in patients with postoperative intra-abdominal infectious complications following curative gastrectomy for gastric cancer. Ann Surg Oncol. 2013, 20: 1575-1583. 10.1245/s10434-012-2720-9.CrossRefPubMed
38.
go back to reference Li QG, Li P, Tang D, Chen J, Wang DR: Impact of postoperative complications on long-term survival after radical resection for gastric cancer. World J Gastroenterol. 2013, 19: 4060-4065. 10.3748/wjg.v19.i25.4060.CrossRefPubMedPubMedCentral Li QG, Li P, Tang D, Chen J, Wang DR: Impact of postoperative complications on long-term survival after radical resection for gastric cancer. World J Gastroenterol. 2013, 19: 4060-4065. 10.3748/wjg.v19.i25.4060.CrossRefPubMedPubMedCentral
Metadata
Title
Long term follow up and retrospective study on 533 gastric cancer cases
Authors
Wei-Juan Zeng
Wen-Qin Hu
Lin-Wei Wang
Shu-Guang Yan
Jian-Ding Li
Hao-Liang Zhao
Chun-Wei Peng
Gui-Fang Yang
Yan Li
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Surgery / Issue 1/2014
Electronic ISSN: 1471-2482
DOI
https://doi.org/10.1186/1471-2482-14-29

Other articles of this Issue 1/2014

BMC Surgery 1/2014 Go to the issue